BMS-986158
- Generic Name
- BMS-986158
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H33N5O2
- CAS Number
- 1800340-40-2
- Unique Ingredient Identifier
- X8BW0MQ5PI
- Background
BMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 220
- Registration Number
- NCT05372354
- Locations
- 🇨🇦
University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario, Canada
🇺🇸John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 216
- Registration Number
- NCT04817007
- Locations
- 🇷🇴
Local Institution - 0052, Bucuresti, Cluj, Romania
🇷🇴Local Institution - 0083, Bucuresti, Romania
🇷🇴Local Institution - 0051, Cluj, Romania
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT03936465
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Study of BMS-986158 in Subjects With Select Advanced Cancers
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 83
- Registration Number
- NCT02419417
- Locations
- 🇺🇸
Univ. Of Pa, Philadelphia, Pennsylvania, United States
🇺🇸City Of Hope National Medical Center, Duarte, California, United States
🇺🇸Institute for Translational Oncology Research-ITOR, Greenville, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.